Purdue Institute for Drug Discovery

Pipeline Entities Overview

FDA Approved:

Phase 3:

Phase 2:

Phase 1:

Canine PD-L1 Antibody

LMP400 (indotecan)

LMP776 (indimitecan)

Pre-clinical:

DESI diagnostic

Glucagon derivatives

SHP2 inhibitors - oncology

TC-PTP degraders

In Vivo Efficacy:

DGAT2 degraders

GRK2 inhibitors

MPTPB inhibitors

Niclosamide-OHPP

NNMT inhibitors (cancer)

NNMT inhibitors (fibrosis)

NTMT1 inhibitor (muscle)

NTMT1 inhibitor (pain)

PD-L1 degraders

PLCG2 activators

PLS Lung Surfactant

PSMA617-miR-34a

PTPN22 inhibitors

SHP2 inhibitors

SHP2 inhibitors - immunology

Pipeline Entities Overview